Tolera Ambisa Lamesa

Tolera Ambisa Lamesa

Auto-generated profile, based on publicly available information

Tolera Ambisa Lamesa

School of Medical Laboratory Science, Jimma University, Jimma, Ethiopia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in HIV/AIDS - Research and Palliative Care
Verified
Journal Article
Open access
PDF file
TLTolera Ambisa Lamesa
Tolera Ambisa Lamesa
AMAklilu Getachew Mamo
Aklilu Getachew Mamo
GBGebeyaw Arega Berihun
Gebeyaw Arega Berihun
RKRegassa Alemu Kebede
Regassa Alemu Kebede
ELEba Bekele Lemesa
Eba Bekele Lemesa
WGWaqtola Cheneke Gebisa
Waqtola Cheneke Gebisa
Background: Highly active antiretroviral treatment is beneficial to suppress human immune virus replication in infected individuals. However, dyslipidemia and other metabolic abnormalities have emerged due to antiretroviral treatment. The prevalence of dyslipidemia in children and adolescents on antiretroviral treatment varies from 20% to 70%. The lack of data on children and adolescents in Ethiopia was the rationale for conducting this study. We aimed to determine prevalence of dyslipidemia and nutritional status in children and adolescents on follow-up at Jimma medical center. Materials and Methods: A hospital-based cross-sectional study was conducted with 150 children and adolescents on follow-up at Jimma medical center. A systematic sampling technique was employed. An interview was carried out to collect socioeconomic and demographic data and a review of medical records was carried out to collect patients’ clinical data. Anthropometric data were computed using the CDC growth chart. About 3– 5mL of fasting blood was collected to measure lipid profile. Multivariable logistic regression was performed to find the association between risk factors and lipid profile. Results: The overall prevalence of dyslipidemia in this study was 72%. About 72% and 21.3% of study subjects had low high-density lipoprotein and high triglyceride, respectively. Significant associations were observed between BMI for age ≤ 5% (AOR: 2.02, 95% CI: 1.14– 3.66; P=0.015) and low high-density lipoprotein; greater than 150 months on treatment (AOR: 1.02, 95% CI: 1.00– 1.03; P=0.01) and high triglyceride; and BMI for age ≤ 5% (AOR: 1.86, 95% CI: 1.03– 1.37; P=0.04) and high triglyceride. Conclusion: BMI for age < 5%, treatment duration of greater than 150 months, and parents’ educational level were significantly associated with dyslipidemia, so it is recommended that monitoring of those variables will help to reduce dyslipidemia and its complications in children and adolescents receiving treatment.

1 April 2024 in HIV/AIDS - Research and Palliative Care
Verified
Journal Article
Open access
PDF file
TLTolera Lamesa
Tolera Lamesa
Lipodystrophy syndrome is a medical condition characterized by the absence of adipose tissue without any underlying starvation or macromolecule breakdown. In HIV AIDS patients, the use of highly active antiretroviral therapy (HAART) can lead to an acquired form of lipodystrophy, with a prevalence ranging from 10% to 83% among HIV AIDS patients. It was aimed to review the current understanding of biological depiction and challenges related to lipodystrophy in AIDS patients. Relevant articles published in the English language were searched in PubMed, Google Scholar, and Google. Keywords used for the search were: lipodystrophy, lipodystrophy and HIV, ART and lipodystrophy, HIV treatment, metabolic syndrome and HIV. Articles with full abstract information were read for those that met the objective criteria of the review, then full text of the articles was accessed and used. It was revealed by the literature that patients who developed lipodystrophy are characterized by insulin abnormality, obesity, diabetes mellitus, dyslipidemia, fatty liver disease, and ovarian dysfunction. Anthropometric measurements have been known to change significantly with lipodystrophy. HIV patients suffering from hepatitis C virus, hepatitis B virus, who take a protease inhibitor, are changing treatment or duration of treatment, and are women are the common risk factors for lipodystrophy. The metabolic syndrome seen in HIV patients associated with lipodystrophy can further be complicated to different adverse health effects and can result in increased morbidity and mortality rate if not treated. Existing studies have successfully identified several challenges faced by HIV AIDS patients due to lipodystrophy, including low self-esteem, compromised quality of life, and poor treatment adherence. However, it is crucial to acknowledge that there may be numerous other challenges that have yet to be discovered, emphasizing the need for further studies. It is recommended that managing dyslipidemia, treating diabetes mellitus, modifying lifestyle, and improving the anthropometric measurements have crucial roles to halt further complications associated with lipodystrophy.

24 June 2025 in PLOS ONE
Verified
Journal Article
Open access
NRNegesse Bokona Rufe
Negesse Bokona Rufe
TLTolera Ambisa Lamesa
Tolera Ambisa Lamesa
AMAklilu Getachew Mamo
Aklilu Getachew Mamo
BZBelay Merkeb Zewude
Belay Merkeb Zewude
BABedasa Addisu
Bedasa Addisu
Sintayehu Asaye BiyaSintayehu Asaye Biya
Sintayehu Asaye Biya
Background: Despite evidence suggesting that hyperuricemia (serum uric acid >7.0 mg/dL in males and >6.0 mg/dL in females) contributes to adverse outcomes like mortality and hospitalization in patients with cardiovascular disease (CVD), a comprehensive understanding of its magnitude is still lacking, underscoring the need for further investigation. There is no previously published study about hyperuricemia in cardiovascular disease in Ethiopia. Therefore, this study aims to investigate the prevalence of hyperuricemia and its associated factors among adult patients with cardiovascular diseases at Salale University Compressive Specialized Hospital Located in Fitche, Ethiopia (115 km north of Addis Ababa),from October 1, 2023, to January 28, 2024. Materials and methods: A hospital-based cross-sectional study was conducted on 298 participants with different types of cardiovascular disease. The participants were selected using a consecutive sampling technique. Socio-demographic factors were collected using interviewer-administered questionnaires, while overnight blood samples were collected and biochemical tests were analyzed using the COBAS c 311 automated clinical chemistry analyzer. Descriptive statistics and logistic regression analyses were performed. A variable that had a p-value of ≤ 0.05 with a 95% confidence interval was considered statistically significant. Result: The prevalence of hyperuricemia among adult cardiovascular disease patients was 41.3% CI [35.6–47.1]. The highest prevalence of hyperuricemia was found among cardiovascular disease patients with congestive heart failure (48.0%) and hypertensive heart disease (41.2%). Factors such as physical activity (AOR: 4.1; 95% CI: 1.5–10.7, P = 0.004), dyslipidemia (AOR: 2.7; 95% CI: 1.2–6.0, P = 0.01) and chronic kidney disease (AOR: 3.1; 95% CI: 1.5–6.1, P = 0.001) were found to be associated with hyperuricemia among individuals with cardiovascular disease. Conclusion: The study indicated a high prevalence of hyperuricemia among participants with cardiovascular disease. Physical activity, dyslipidemia, and chronic kidney disease were recognized as significant associated factors of hyperuricemia among cardiovascular disease. Therefore, early diagnosis of hyperuricemia and its management is essential to control complications and extend the life expectancy of individuals with cardiovascular disease.

1 February 2024 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
RKRegassa Alemu Kebede
Regassa Alemu Kebede
TYTilahun Yemane
Tilahun Yemane
GBGebeyaw Arega Berihun
Gebeyaw Arega Berihun
TLTolera Ambisa Lamesa
Tolera Ambisa Lamesa
DRDereje Abebe Regasa
Dereje Abebe Regasa
Background: Anemia is among the major public health problems that cause significant morbidity and mortality among children around the world. Anemia in children of age 6 months to 5 years is a major health problem in most developing world countries with estimated prevalence of about 43%. Objective: To determine the magnitude, associated factors and morphological types of anemia among hospitalized 6– 59 months age children from June 15 to October 15, 2022 at Jimma Medical Center, southwest Ethiopia. Methodology: Hospital-based cross- sectional study design was conducted from June 15 to October 15, 2022 at Jimma Medical Center, involving 383 hospitalized children aged 6– 59 months by employing convenient sampling technique. Data of sociodemographic characteristics and other associated factors of the study individuals waere collected using a pre-structured questionnaire. Clinical data were collected by physical examination and from history of client by medical interns and nurses. Then 3 mL venous blood was collected and analyzed for complete blood count. Data were coded, cleared and entered into EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable binary logistic regression was used to identify associated factors. Results: The overall prevalence of anemia among hospitalized 6– 59 months age children was 57.2%; out of them 30.82% were moderate. In the present study children with malaria infection, AOR = 1.15 (95% CI: 0.017, 0.781), Cchildren with severe malnutrition, AOR = 2.046 (95% CI: 0.306, 1.366), and children with low family income, AOR = 2.6 (95% CI 0.475, 0.894) were independent variables associated with anemia. Conclusion and Recommendation: Anemia among study participants is found to be a severe public health problem. Based on this finding, more intervention is needed with health education on nutrition and child feeding.

8 March 2025 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Open access
TLTolera Ambisa Lamesa
Tolera Ambisa Lamesa
Human Immunodeficiency Viruses (HIV) infected people are at increased chance of immunocompromission. In combination with this immunocompromission, the incidence of co-infection with intestinal parasites, intestinal protozoal and Helicobacter pylori can be escalated by different factors including similar mode of transmission, poor economic status, synergistic pathogenesis, and geographic topography of more than two organisms. A large number of world population is either affected or at risk of infection from diversified intestinal parasites, intestinal protozoal and H. pylori. The study determined the prevalence of H. pylori with intestinal parasites and intestinal protozoal co-infection among HIV positive individuals and factors associated to the co-infection at Jimma University Medical Center (JUMC); Jimma, Ethiopia. This cross-sectional study included 384 HIV positive patients using consecutive sampling technique. Stool sample was examined using normal saline to diagnosis intestinal parasites and with lugol's Iodine for active motile intestinal protozoa and the stool sample was concentrated by formalin-ethyl acetate and stained with Kinyoun-modified acid-fast stain to stain coccidian protozoa H. pylori was diagnosed by antigen test using Wondfo one Step H. pylori feces test. In this study, gender distribution was 177(46.1 %) males and 207(53.9 %) females. About 179 were between 10 and 20 years. The prevalence of H. pylori, intestinal parasites and intestinal protozoal infection among HIV positive individuals were 27.6 % 24.4 % and 6.5 % respectively. The overall prevalence of both intestinal parasites and intestinal protozoal co-infection with H. pylori was 20.7 %. Positive associations of co-infection with source of drinking water, animal contact, finger nail trimming, economic status and shoe-wearing habits as significant variables. A notable co-infection involving H. Pylori alongside intestinal parasites and intestinal protozoa was identified. It was acknowledged that the sanitary and socio-economic conditions could serve as potential risk factors associated with co-infection. Enhancing hygiene and sanitation practices is essential to interrupt the transmission pathways of intestinal parasites, H. Pylori, and intestinal protozoa, particularly for individuals with weakened immune systems, including those living with AIDS.